Literature DB >> 2901758

Antagonism of clonidine-induced hypothermia by alpha adrenoceptor antagonists in electrically stimulated mice.

A Y Junnarkar1, P P Singh.   

Abstract

The involvement of receptor subtypes in clonidine-induced hypothermia in electrically stimulated mice was studied using various alpha-adrenoceptor antagonists. Yohimbine, the selective alpha 2-adrenoceptor antagonist significantly blocked the action of low dose (50 micrograms/kg i.p.) of clonidine pretreated with Minimal Threshold Shock (12 mA, 0.2 Sec), while prazosin, selective alpha 1-adrenoceptor antagonist partially blocked the action, suggesting predominant involvement of alpha 2 and partial involvement of alpha 1-adrenoceptors. Under similar conditions when clonidine was used in higher dose (500 micrograms/kg i.p.), its action was blocked by prazosin, phenoxybenzamine and yohimbine suggesting involvement of both alpha 1 and alpha 2-adrenoceptors. In case of animals pretreated with Maximal Threshold Shock (36 mA, 0.2 Sec) the hypothermic action of clonidine in lower dose was blocked by all the three antagonists viz. prazosin, phenoxybenzamine and yohimbine, suggesting involvement of both alpha 1 and alpha 2-adrenoceptors, however, when clonidine was used in the higher dose, the action was significantly antagonised by prazosin and partially by yohimbine, suggesting predominant involvement of alpha 1 and partial involvement of alpha 2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901758     DOI: 10.1016/s0031-6989(88)80074-2

Source DB:  PubMed          Journal:  Pharmacol Res Commun        ISSN: 0031-6989


  2 in total

1.  Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin.

Authors:  Theodoros Kelesidis; Iosif Kelesidis
Journal:  Clin Ther       Date:  2009-12       Impact factor: 3.393

2.  Characterization of the hypothermic effects of imidazoline I₂ receptor agonists in rats.

Authors:  David A Thorn; Xiao-Fei An; Yanan Zhang; Maria Pigini; Jun-Xu Li
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.